Kishan Mehta - 01 Dec 2025 Form 4 Insider Report for Benitec Biopharma Inc. (BNTC)

Role
Director
Signature
/s/ Kishan Mehta
Issuer symbol
BNTC
Transactions as of
01 Dec 2025
Transactions value $
$0
Form type
4
Filing time
03 Dec 2025, 16:19:44 UTC
Previous filing
07 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mehta Kishan Director C/O BENITEC BIOPHARMA INC., 3940 TRUST WAY, HAYWARD /s/ Kishan Mehta 03 Dec 2025 0001850520

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BNTC Options (right to buy) Award $0 +35,000 $0 35,000 01 Dec 2025 Common Stock 35,000 $12.23 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Mehta in connection with his role as a member of the Issuer's Board of Directors. Mr. Mehta, as Portfolio Manager for Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds") is holding such options for the benefit of the Funds, and as such Mr. Mehta disclaims beneficial ownership of such options. The Funds, and Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Mehta's board service.
F2 The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.